Square Pharma recommends record 130pc cash dividend

Square Pharmaceuticals, the country’s leading drug maker, has recommended a record 130 per cent cash dividend for the financial year 2025-26 (FY26).

The company’s board of directors recommended the dividend at a meeting on Monday while reviewing the financial statements for the year.

The company distributed a 120 per cent cash dividend in FY25, 110 per cent in FY24 and 105 per cent in FY23.

Square Pharmaceuticals also posted a 19.35 per cent year-on-year growth in profit in FY26, driven by higher revenue.